Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00417066
Status:
COMPLETED
Last Update Posted:
2013-12-16
First Post:
2006-12-22
Brief Title:
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
Sponsor:
Eugonia
Organization:
Eugonia
Study Overview
Official Title:
The Flexible GnRH Antagonist Protocol Provides Better Results IVF Outcomes Than Flare up GnRH Agonist Protocol in Poor Responders
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare ovulation induction using a flexible GnRH antagonist protocol and flare up GnRH agonist protocol in IVF patients with poor response to ovarian stimulation Our hypothesis is that the antagonist protocol provides better IVF outcomes compared to the flare up protocol in this group of patients
Detailed Description:
Poor responders are women who fail to respond effectively to the usual gonadotropin stimulation protocol applied in an IVF cycle It seems that a diminished ovarian reserve is the principal factor of poor ovarian response Several strategies have been proposed for the management of poor responders including flare up GnRH agonist regimens and the GnRH antagonist which presents a new hope in this group of patients
Comparisons Poor responder patients see inclusion criteria commencing an IVF treatment cyle will receive ovarian stimulation treatment either using a GnRH antagonist Ganirelix or flare up agonist Arvekap protocol Primary outcomes compared will be ongoing pregnancy rates in the two treatment groups
Comparisons Poor responder patients see inclusion criteria commencing an IVF treatment cyle will receive ovarian stimulation treatment either using a GnRH antagonist Ganirelix or flare up agonist Arvekap protocol Primary outcomes compared will be ongoing pregnancy rates in the two treatment groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None